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Genetic testing, at some level, has been around since at least the early 
1900s. By definition, it involves the analysis of human DNA, RNA, 
chromosomes, proteins and certain metabolites to detect heritable 
disease-related genotypes, mutations, phenotypes or karyotypes for 
clinical reasons. Recent technological advances, particularly next-
generation sequencing (NGS), have resulted in rapidly reduced costs 
per base of DNA analysed, with much higher levels of resolution, 
enhancing the availability and scope of genetic testing, especially 
for single-gene disorders. These tests offer patients and doctors new 
and improved opportunities for definitive diagnoses and improved 
management, while putting an end to long diagnostic odysseys. 
It can be complex to choose the correct test for a patient, 
and the choices can be confusing and overwhelming. Scope for 
misinterpretation and inappropriate testing is also higher. Although 
laboratory ‘wet’ test technology is being increasingly automated, the 
challenges of analysis, storage and interpretation of large amounts 
of data are considerable and require highly trained scientists and 
bioinformaticists. They need to work with genetic counsellors 
and medical geneticists – in this way the information is accurately 
interpreted and its clinical relevance is assessed.
The fundamental reasons for performing genetic testing remain 
unchanged. Patients and doctors require a definitive diagnosis for 
optimum management. Furthermore, individuals and families have 
major concerns regarding risks of occurrence and recurrence of 
genetic disorders. These requirements necessitate appropriate and 
accurate genetic testing, facilitated by individuals trained in medical 
genetics and genetic counselling, with detailed knowledge of clinical 
genetic assessment of patients, choice of tests and interpretation of 
results.
Testing by DNA analysis offers advantages over testing of other 
metabolites, as DNA remains unchanged from conception to death, 
and is typically the same in all tissues. Other metabolites may only 
be measurable once a disease manifests. Thus, DNA analysis can be 
performed definitively, once-off and at any stage of life and provides 
the same results. This necessitates extremely high-level laboratory 
practice, such that errors are minimised. 
Indications for genetic testing
There are a number of broad indications for genetic testing:
• Diagnostic testing can confirm or rule out a known or suspected 
genetic disorder in a symptomatic individual. 
• Predictive or presymptomatic testing can be offered to asymp-
tomatic individuals to refine their risk of developing a condition 
later in life. 
• Carrier testing identifies individuals who carry autosomal or 
X-linked recessive mutations, and who may be at risk of having 
children with a genetic disorder.
• Prenatal or pre-implantation testing is performed prior to or 
during a pregnancy to assess the health status of a fetus or embryo.
The changing face of genetic testing
Genetic testing by DNA analysis has been available for an increasing 
number of single-gene disorders since the mid-1980s. These tests 
were specifically directed at a single gene or part of a gene. They 
tested for common mutations or family-specific mutations, or 
sequenced a relatively small amount of DNA to identify unknown 
mutations. Typically, no more than 2 - 3 genes would have been 
analysed simultaneously, owing to the relatively high costs and 
time to do the analysis. However, results had a high certainty of a 
predictable result, and it was relatively easy to compare laboratories 
and quality of results. 
Currently, new NGS technologies offer an increasing ability to 
make accurate diagnoses for single-gene disorders, as multiple 
genetic analyses can be performed simultaneously. Testing is thus less 
hypothesis driven. Patients who have rare mutations have improved 
chances of obtaining diagnoses, complex genetic interactions are being 
increasingly recognised and new disease-associated genes are being 
identified. This ultimately translates into improved understanding of 
genetic causation of disease and more accurate individual and family-
risk assessment. Testing remains relatively expensive, although the 
cost per base of DNA sequenced has reduced dramatically. The 
required equipment is expensive to run and maintain. NGS data also 
remain challenging to interpret owing to the size and complexity 
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of the genome and the technical errors that are introduced during 
sample preparation, sequencing and analysis. These errors can be 
somewhat mitigated by the use of reference standards for validation 
and quality control. However, such standards and filtering may also 
increase the proportion of false-negative results, which represent 
missed opportunities for diagnosis. Certain sequencing artifacts and 
short-read misalignment cannot easily be overcome. Furthermore, it 
is difficult to compare the quality of sequencing offered by different 
laboratories, as many of these metrics are not standardly provided. 
How is a genetic test chosen?
Testing should prioritise the patient’s needs. Currently, from a 
diagnostic point of view, an older single-gene test may in many cases 
still provide the fastest and most definitive result, with the least 
ambiguity. More extensive testing is not necessarily better. Genetic 
testing should not be performed in the absence of good clinical 
phenotyping, as correlation of genetic and clinical data is key to 
interpretation. 
The choice of the most appropriate test for a patient can be 
somewhat overwhelming, as the technologies, test designs, sequence 
coverage (how much of a gene(s) of interest is sequenced) and 
depth of coverage (related to accuracy) may differ and not be easily 
accessible. As each test level offers more analysis, the temptation is to 
choose a test with more data rather than one with less, in the hope of 
a higher likelihood of a positive result. This is certainly not always the 
case. The data sets are extremely large, and the analysis is extremely 
complex and time-consuming. 
There are three broad categories of NGS tests available, each 
adding a successively larger data load for arguably diminishing 
diagnostic return:
• Gene-panel testing can be helpful in scenarios where the patient’s 
clinical features are relatively distinct and multiple genes are 
known to cause a similar phenotype in different individuals. In 
such cases, a so-called panel of selected genes can be analysed 
simultaneously. Panels may contain only a few genes or several 
hundred genes. Such gene-panel tests have a high diagnostic 
yield if carefully selected and appropriate patients with suggestive 
clinical features are tested. The panels tend to provide results with 
high clinical certainty and little ambiguity, e.g. muscular dystrophy, 
familial cancer or epilepsy gene panels.
• Whole-exome sequencing (WES) includes the analysis of sequence 
of the entire coding region of the human genome (~50 million DNA 
bases), with no analysis of non-coding DNA. In this analysis, 1 - 
2% of the genome is analysed, with the advantage that ~85% of 
pathogenic mutations are located in exons, with a predicted high 
diagnostic yield. Such analysis may be required when a patient’s 
phenotype is relatively poorly defined or a new syndrome is 
suspected. However, interpretation can be very challenging and 
should not be undertaken without consultation with experts in 
genetics. 
• Whole-genome sequencing (WGS) covers all 3 000 million bases 
of human DNA. This analysis obviously generates a massive 
dataset and a very large number of variants, which would need 
to be analysed. It has the potential to identify genetic mutations 
outside the coding regions (e.g. in introns), or where large 
structural rearrangements are responsible, but is largely a research 
technique that currently has few clinical indications, particularly 
as our knowledge of the role of non-coding DNA is rather limited.
It is also important to always consider the implications of a negative 
test. Despite the highest quality testing, patients with features highly 
suggestive of a genetic condition may test negative and thus a negative 
test does not exclude a genetic cause. The reasons for negative tests 
are not always clear, but may be a combination of missed mutations 
due to, among other factors, technical issues (parts of the genome 
do not get sequenced owing to their complex structure), large 
rearrangements and deletions that are difficult to detect with current 
NGS techniques, misinterpretation and epigenetic modifications 
of DNA (where the sequence is unchanged). There may also be 
mutations in a regulatory region or regions currently not thought to 
have functional significance.
Chromosomal microarray analysis is an important genetic test 
that is now considered the gold standard for detecting chromosomal 
abnormalities. It has increased the identification and resolution of 
large chromosomal deletions, duplications and rearrangements, 
typically involving a number of genes. It is often the first test indicated 
in individuals with developmental delay and other congenital 
abnormalities. NGS techniques are currently poor at detecting such 
abnormalities and therefore microarray analysis is often performed 
prior to NGS or as a complementary test to an NGS-based test, 
particularly if a large (non-single gene) abnormality is suspected. 
Interpretation of genetic tests
A large number of genetic variants are likely to be identified in 
any analysis. We are currently in a phase where our technological 
capabilities outstrip our knowledge and interpretive capabilities. A 
proportion of variants analysed in any test would be benign, and part 
of normal inter-individual variation. These need to be distinguished 
from those that are pathogenic. However, the pathological 
significance of genetic variants may be unclear (so-called variants 
of unknown significance (VUSs)). Such VUSs can be extremely 
frustrating for doctors and patients alike, as they do not assist with 
diagnosis or management, but can cause enormous anxiety and may 
trigger downstream testing, which may not assist with clarification. 
Laboratories may choose to report VUSs or not. The reporting needs 
to be balanced between reporting too little, which potentially risks 
missing a diagnosis, and reporting too many VUSs, leading to the 
potential for the mis- and overdiagnosis of patients, a factor that 
clinicians need to be aware of. As the field progresses, reporting 
VUSs may become more prominent by laboratories that wish to limit 
liability. However, as more patients have sequencing performed and 
knowledge increases, our ability to classify variants should improve, 
thus reducing the reporting of VUSs. 
Interpretation of variants is complex and influenced by experience 
and an understanding of how mutations in a particular gene alter 
its function and cause disease. This could lead to the same variant 
being classified differently in different laboratories. Interpretations 
also change with time, as knowledge accumulates. This raises the 
issue of the value of re-analysis of genetic data. It is unclear whose 
responsibility it should be to initiate re-analysis; there are also no 
guidelines as to how frequently it should be done. Data are being 
gathered very rapidly and interpretation of a variant may thus change 
with time. 
Unexpected findings from genetic 
testing
As large amounts of genomic data may be analysed in a test in 
search of the causative genetic fault, other unexpected incidental or 
secondary findings may be identified. These may be unrelated to the 
original indication for testing, but are of medical value for patient 
care. The possibilities of such findings need to be raised with patients 
in advance of testing. However, difficulties may arise as to which 
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findings should be conveyed to patients and when. For example, 
should information about adult-onset diseases be conveyed to 
children? Individuals may be frustrated by a test that does not provide 
an answer for their clinical problem, but raises additional medical 
concerns, which now have to be dealt with. It is estimated that ~1% 
of broad NGS-based genetic tests may reveal a reportable incidental 
variant. Some guidelines regarding incidental findings do exist, 
although they are by no means standardised. One such example is the 
American College of Medical Genetics (ACMG) reportable/actionable 
list of 59 genes. These genes include those associated with inherited 
cancer syndromes, cardiomyopathy, familial hypercholesterolaemia 
and Marfan syndrome. It obligates clinicians/genetic counsellors to 
report pathogenic and likely pathogenic variants in these genes to 
patients. However, there is currently little consensus across different 
centres with regard to these practices. Others recommend that data 
should not be analysed for such findings. 
If a laboratory chooses to actively search for secondary findings, 
this should be performed separately from the original analysis and 
only if prior informed consent has been obtained from the patient. If 
carrier status is identified in adults, some recommend that it should 
be reported, as it may impact on reproductive options. It may also 
cause anxiety, as testing the partner in a recessive condition may be 
time-consuming, expensive and not provide reassuring answers.
Challenges of genetic testing in Africa
Genetic testing in individuals with African ancestry currently raises 
particular challenges. Critical to determining pathogenicity of 
variants is to compare their occurrence in patients and unaffected 
individuals. The paucity of data from normal individuals in Africa 
and the extensive genetic diversity on the continent make the 
possibility of finding a VUS significantly higher. There is an urgent 
need for diagnostic laboratories to collaborate and establish national 
data resources to ensure storage of data and sharing of variants so that 
interpretation on the African continent can be optimised. 
Furthermore, there is little epidemiological knowledge regarding 
genetic disease in Africa, which makes it difficult to know which 
conditions should be prioritised for testing. Research projects such as 
those funded by the Human Heredity and Health in Africa (H3Africa) 
initiatives are beginning to address these issues. Examples include 
the Deciphering Developmental Disorders in Africa (DDD-Africa) 
project, a joint venture between the University of the Witwatersrand, 
South Africa, and the University of Kinshasa, Democratic Republic of 
the Congo. Initiatives to study deafness and neurological disease in 
Africa have also been initiated (https://h3africa.org/). These projects 
will ultimately lead to increased knowledge and more directed 
diagnostic approaches in Africa. 
Conclusion
Genetic testing is increasingly available for a broad range of 
conditions. Choice of tests is complex. Interpretation of tests is 
highly reliant on sound clinical information and assessment, as well 
as skilled laboratory and genetic personnel. The most appropriate test 
should be chosen to optimise results and minimise uninterpretable or 
unwanted findings. The same results may be interpreted differently 
with time as knowledge increases. Many challenges remain, including 
technical, interpretative and ethical ones. Medical geneticists and 
genetic counsellors have extensive training in genetics, with detailed 
knowledge in clinical genetic assessment of patients, choice of tests 
and interpretation of results, and should be involved in such testing 
to ensure patients receive optimal care. Genetic testing promises to 
contribute enormously to improved patient diagnosis in the next few 
years, as our understanding of genetic disease expands and our ability 
to manage and interpret data improves. 
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